Estrella CEO exercises 100K options at $0.815
Estrella Immunopharma, Inc. (ESLA) reported that CEO and director Liu Cheng exercised stock options for 100,000 shares of common stock on 2026-08-25 at an exercise price of $0.815 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Estrella Immunopharma, Inc. (ESLA) reported that CEO and director Liu Cheng exercised stock options for 100,000 shares of common stock on 2026-08-25 at an exercise price of $0.815 per share. Following the exercise, Cheng directly holds 397,437 shares of common stock and 900,000 incentive stock options related to this award remain outstanding.
The options were granted on 2024-10-30 under the 2023 Omnibus Incentive Plan, with 25% immediately exercisable at grant and the remainder vesting in equal monthly installments of 1/48th of the total award; the options exercised were vested.
Insider Trade Summary
100,000 shares exercised/converted
Exercise
2 txns
Insider
Liu Cheng
Role
CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Incentive Stock Option F3, F4 | 100,000 | $0.00 | $0.00 |
| Exercise | Common Stock, par value $0.0001 per share F1, F2 | 100,000 | $0.815 | $82K |
Holdings After Transaction:
Incentive Stock Option — 900,000 contracts (Direct);
Common Stock, par value $0.0001 per share — 397,437 shares (Direct)
Footnotes (4)
- F1. Represents the exercise price per share paid by the Reporting Person upon the exercise of the stock options reported in Table II.
- F2. Reflects the 297,437 shares of Common Stock directly beneficially owned as reported on the Reporting Person's most recent Form 4, plus the 100,000 shares acquired upon the reported exercise.
- F3. Represents incentive share options granted to the Reporting Person on October 30, 2024 under the Issuer's 2023 Omnibus Incentive Plan, of which twenty-five percent (25%) was immediately exercisable on the date of grant, with the remainder vesting in equal monthly installments of 1/48th of the total award on each monthly anniversary of October 30, 2024. The options were vested as to the shares exercised.
- F4. Not applicable. The reported transaction is the exercise of the stock option for the exercise price set forth in Column 2. No separate consideration was paid or received for the derivative security.
Key Figures
Options Exercised: 100,000 shares
Exercise Price: $0.815 per share
Common Shares Held After Transaction: 397,437 shares
+4 more
7 metrics
Options Exercised
100,000 shares
Incentive stock options exercised on 2026-08-25
Exercise Price
$0.815 per share
Exercise price paid for the 100,000 options
Common Shares Held After Transaction
397,437 shares
Directly beneficially owned by Liu Cheng after exercise
Derivative Securities Following Transaction
900,000 incentive stock options
Total related options beneficially owned after exercise
Grant Date of Options
2024-10-30
Incentive stock options grant under 2023 Omnibus Incentive Plan
Option Expiration Date
2034-10-29
Expiration of the incentive stock options exercised
Immediate Vesting Portion
25%
Portion of award exercisable on grant date
Key Terms
Incentive Stock Option, 2023 Omnibus Incentive Plan, beneficially owned, exercise price, +1 more
5 terms
Incentive Stock Option financial
"Represents incentive share options granted to the Reporting Person"
An incentive stock option is a type of employee benefit that gives a worker the right to buy company shares at a fixed price, with special tax advantages if the employee holds the shares for a required period. Think of it as a coupon to buy future shares at today’s price that can result in lower tax on the gain. Investors care because ISOs can dilute share count, align staff incentives with the stock price, and affect company compensation costs and the timing of potential share sales.
2023 Omnibus Incentive Plan financial
"granted to the Reporting Person on October 30, 2024 under the Issuer's 2023 Omnibus Incentive Plan"
beneficially owned financial
"Reflects the 297,437 shares of Common Stock directly beneficially owned"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
exercise price financial
"Represents the exercise price per share paid by the Reporting Person"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
derivative security financial
"No separate consideration was paid or received for the derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did ESLA CEO Liu Cheng report on this Form 4?
Liu Cheng reported exercising incentive stock options for 100,000 shares of Estrella Immunopharma common stock on 2026-08-25, converting them at an exercise price of $0.815 per share into directly held common shares.
What options did Liu Cheng exercise in Estrella Immunopharma (ESLA)?
He exercised 100,000 incentive stock options granted on 2024-10-30 under Estrella Immunopharma’s 2023 Omnibus Incentive Plan, at an exercise price of $0.815 per share, into an equal number of common shares.
What is the vesting schedule of Liu Cheng’s ESLA incentive stock options?
The filing states that 25% of the options were immediately exercisable on the 2024-10-30 grant date, with the remaining 75% vesting in equal monthly installments of 1/48th of the total award on each monthly anniversary of that date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
